Return to search results
Belumosudil
Rezurock is the brand name for belumosudil, an oral prescription tablet manufactured by Kadmon Pharmaceuticals, LLC. Each tablet contains 200 mg of belumosudil and was approved under NDA214783, with marketing starting in July 2021. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Rezurock is the brand name for belumosudil, an oral prescription tablet manufactured by Kadmon Pharmaceuticals, LLC. Each tablet contains 200 mg of belumosudil and was approved under NDA214783, with marketing starting in July 2021. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Belumosudil",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Belumosudil — ANDA 214783 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214783"
}
]
|
| identifier | ANDA214783 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-manufacturers",
"fda",
"medications",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Belumosudil |
